Literature DB >> 27612602

Soluble sortilin is present in excess and positively correlates with progranulin in CSF of aging individuals.

Simon Molgaard1, Ditte Demontis2, Alexandra M Nicholson3, Nicole A Finch3, Ronald C Petersen4, Claus M Petersen5, Rosa Rademakers3, Anders Nykjaer6, Simon Glerup7.   

Abstract

Mutations in progranulin are a major cause of frontotemporal lobe degeneration (FTLD). Hence, plasma progranulin is an attractive biomarker in FTLD but poorly reflects levels in cerebrospinal fluid (CSF), suggesting tissue-specific regulation of progranulin levels. Sortilin was recently identified as a progranulin scavenger receptor that destines it for lysosomal degradation. Proteolysis or alternative splicing generates soluble sortilin variants that retain progranulin binding and potentially functions as a decoy receptor. In the present study, we analyzed soluble sortilin and progranulin in plasma and CSF in 341 aging individuals. We found that soluble sortilin exists in CSF in ten-fold molar excess compared to progranulin and observed a highly significant positive correlation between soluble sortilin and progranulin levels in CSF but not in plasma. However, carriers of the minor allele of SNP rs646776 in SORT1 encoding sortilin displayed significantly increased soluble sortilin and reduced progranulin specifically in plasma but not in CSF. Taken together, our findings suggest that soluble sortilin may affect progranulin levels in both a tissue-specific and genotype-dependent manner.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Biomarker; Decoy receptor; ELISA; Frontotemporal lobar degeneration; Progranulin; Single nucleotide polymorphism; Sortilin

Mesh:

Substances:

Year:  2016        PMID: 27612602     DOI: 10.1016/j.exger.2016.09.002

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  7 in total

1.  Abnormal TDP-43 function impairs activity-dependent BDNF secretion, synaptic plasticity, and cognitive behavior through altered Sortilin splicing.

Authors:  Jason Y Tann; Lik-Wei Wong; Sreedharan Sajikumar; Carlos F Ibáñez
Journal:  EMBO J       Date:  2019-01-28       Impact factor: 11.598

Review 2.  Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.

Authors:  Sophie Béraud-Dufour; Chistelle Devader; Fabienne Massa; Morgane Roulot; Thierry Coppola; Jean Mazella
Journal:  Int J Mol Sci       Date:  2016-11-08       Impact factor: 5.923

3.  Sortilin Fragments Deposit at Senile Plaques in Human Cerebrum.

Authors:  Xia Hu; Zhao-Lan Hu; Zheng Li; Chun-Sheng Ruan; Wen-Ying Qiu; Aihua Pan; Chang-Qi Li; Yan Cai; Lu Shen; Yaping Chu; Bei-Sha Tang; Huaibin Cai; Xin-Fu Zhou; Chao Ma; Xiao-Xin Yan
Journal:  Front Neuroanat       Date:  2017-06-07       Impact factor: 3.856

4.  Sortilin gates neurotensin and BDNF signaling to control peripheral neuropathic pain.

Authors:  Mette Richner; Lone T Pallesen; Maj Ulrichsen; Ebbe T Poulsen; Thomas H Holm; Hande Login; Annie Castonguay; Louis-Etienne Lorenzo; Nádia P Gonçalves; Olav M Andersen; Karin Lykke-Hartmann; Jan J Enghild; Lars C B Rønn; Ibrahim J Malik; Yves De Koninck; Ole J Bjerrum; Christian B Vægter; Anders Nykjær
Journal:  Sci Adv       Date:  2019-06-19       Impact factor: 14.136

5.  Inter-Species Differences in Regulation of the Progranulin-Sortilin Axis in TDP-43 Cell Models of Neurodegeneration.

Authors:  Valentina Gumina; Elisa Onesto; Claudia Colombrita; AnnaMaria Maraschi; Vincenzo Silani; Antonia Ratti
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

Review 6.  Deciphering Mechanisms of Action of Sortilin/Neurotensin Receptor-3 in the Proliferation Regulation of Colorectal and Other Cancers.

Authors:  Jean Mazella
Journal:  Int J Mol Sci       Date:  2022-10-06       Impact factor: 6.208

7.  CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Authors:  Marc Suárez-Calvet; Anja Capell; Miguel Ángel Araque Caballero; Estrella Morenas-Rodríguez; Katrin Fellerer; Nicolai Franzmeier; Gernot Kleinberger; Erden Eren; Yuetiva Deming; Laura Piccio; Celeste M Karch; Carlos Cruchaga; Katrina Paumier; Randall J Bateman; Anne M Fagan; John C Morris; Johannes Levin; Adrian Danek; Mathias Jucker; Colin L Masters; Martin N Rossor; John M Ringman; Leslie M Shaw; John Q Trojanowski; Michael Weiner; Michael Ewers; Christian Haass
Journal:  EMBO Mol Med       Date:  2018-12       Impact factor: 12.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.